Connect with us

News

Opinion: Why women’s health needs transformational, not incremental, change

Published

on

Hope Khoury, COO of product development firm Go Vertical ICM, urges faster and more prevention-focused improvement of women’s healthcare globally.

Women’s health has languished long enough in medicine, with millions underserved, misunderstood, and having to struggle with a system that too frequently doesn’t comprehend the entirety of female physiology.

Although recent years have brought us an onslaught of new awareness, how much further there is to ascend remains sizable, especially for diseases that are still underfunded, misdiagnosed, or altogether overlooked.

As a person who has struggled firsthand with the impact of uterine fibroids—a struggle that transformed my whole life—I understand intimately how incapacitating these conditions can be.

My personal ordeal started at 28 when I was diagnosed with a life-threatening 18 cm fibroid. It was not only a health emergency; it was an eye-opener to the systemic disregard for women’s reproductive well-being.

My mother had a hysterectomy at age 43, and I assumed that’s where I was going, too. Rather than accept limited options, though, I began making some choices of my own.

A silent epidemic

Uterine fibroids affect as many as 80% of women by the time they reach 50, and still, the condition is under-discussed and under-researched. Symptoms—chronic pain, excessive menstrual bleeding, infertility, and a reduced quality of life—are disabling, and yet treatments are too often limited to invasive surgeries or hormone therapies that introduce their own risks and side effects.

The bigger question is: why are we still dealing with women’s health on a reactive, rather than proactive, basis? Why is there so little emphasis on prevention? This is not a isolated problem to fibroids alone, but for a vast majority of conditions that affect only women, from endometriosis to PCOS, menopausal issues, and female-onset cancers.

The femtech revolution

One ray of hope lies in the rise of femtech. Yet here too, innovation is held back by a shortage of finance, regulatory hurdles, and the widespread problem of gender bias in medical research.

Even though women comprise more than half of the population, less than 1% of healthcare research funding is allocated to female-specific diseases. And although the femtech market is expected to be valued at more than $50 billion by 2025, the sector continues to attract relatively smaller proportions of investment compared to conventional health and wellness startups.

This inequality is especially troubling when we recognize that innovation in women’s health doesn’t just help women—it helps whole societies. When women are healthy, they’re more productive, more involved, and better able to contribute to their families, workplaces, and communities.

Prevention as the future of women’s health

Following my diagnosis and surgery, I leveraged my training in pharmacology to create a botanical-based supplement that would stop fibroids from growing in the first place.

Prevention needs to be a femtech principle, one that reframes the discussion from symptom management to the underlying causes of disease.

Women deserve solutions that harmonise with their bodies, not fight against them. That involves harnessing the strength of science-proven botanicals, augmenting diagnostic capabilities for early detection, and leveraging technology to provide personalised health information.

AI-powered menstrual tracking, hormone testing, and non-invasive procedures shouldn’t be the future; they should be the now. Alongside better technology, women also need access to trusted spaces where their concerns are taken seriously and treated with care. Resources such as dedicated support for women’s wellbeing play a meaningful role in ensuring that women can seek guidance, treatment, and reassurance without judgement.

I do think that by bringing together scientists, clinicians, and entrepreneurs, we can create a future where women do not have to suffer in silence. The change that we need is not incremental; it has to be transformational.

Hope Khoury is COO of Go Vertical ICM, a firm which helps to guide new products from idea to market.

Diagnosis

Being female not a universal stroke risk factor for patients with AF, study finds

Published

on

Female sex may not raise stroke risk across all atrial fibrillation (AF) patients, with higher risk mainly seen in women aged 75 and older, a study suggests.

Researchers said stroke prevention for women with the condition should be more personalised, especially for patients under 75.

Dr Amitabh C Pandey, director of cardiovascular translational research at Tulane University School of Medicine, said: “For years, female sex has been included as a risk factor along with other factors such as high blood pressure and diabetes, meaning women were more likely to be prescribed anticoagulants.

“Our study shows younger women may not have as much added stroke risk as previously thought, while older women, particularly those over 75, appear to have a higher risk that deserves close attention.”

The new Tulane University study challenges a long-standing assumption in heart care that being female automatically increases stroke risk for patients with atrial fibrillation.

Atrial fibrillation, often called AF, is a common heart rhythm disorder that causes the heart to beat irregularly.

It is associated with a higher risk of stroke and is often treated with anticoagulants, also known as blood thinners.

The study found that stroke risk did not increase equally across all female patients with AF.

Instead, researchers said being female may act more as a risk modifier, with increased stroke risk seen primarily among women aged 75 and older or those with a greater burden of other health conditions.

Clinicians often use a scoring system to decide whether people with AF should be prescribed blood thinners.

The system gives points for factors including age, heart failure, diabetes, previous stroke, vascular disease and high blood pressure.

Women also receive one point for sex alone.

Researchers said this can mean women with AF become eligible for blood thinners earlier or more often than men with otherwise similar risk profiles.

While blood thinners can help prevent clot-related strokes, they can also increase the risk of bruising, prolonged bleeding, gastrointestinal bleeding and other serious complications.

The researchers analysed approximately 950,000 patients with AF using TriNetX, a large anonymised electronic health record database.

They compared stroke outcomes between male and female patients across three age groups: younger than 65, 65 to 74, and 75 and older.

Male and female patients were matched based on age, other health problems and whether they had been prescribed anticoagulation medicine.

Among patients younger than 75, the study found no significant difference in one-year stroke risk between men and women.

However, among patients aged 75 and older, women had a modest but statistically significant increase in stroke risk compared with men.

In patients aged 75 and older with no additional risk factors beyond age, women had about one additional stroke per 629 patients compared with their male counterparts.

The findings support growing interest in a newer AF risk score, known as CHA2DS2-VA, which removes sex as a standalone risk factor.

However, researchers said more studies are needed and medical guidance remains inconsistent.

Han Feng, assistant professor at Tulane University School of Medicine, said: “This general approach came from women being underrepresented in AFib trials and studies comprising only about one-third of study populations.

“Our study shows not all women with AFib have the same risk profile, and these decisions should be individualised.

Pandey said: “These findings highlight the need for modern tools and approaches that can personalise risk profiles to individuals.

“The goal is not to undertreat patients who need stroke prevention, but to better identify who is most likely to benefit from anticoagulation and who may be exposed to unnecessary risk.”

Continue Reading

Diagnosis

AI may help accelerate breast cancer diagnosis for high-risk women – study

Published

on

AI may help speed breast cancer diagnosis for high-risk women after abnormal mammograms, a study suggests.

Women with abnormal mammograms often wait weeks to learn whether they have breast cancer.

Researchers at UC San Francisco and UC Berkeley said an AI-guided workflow could help reduce that wait by quickly identifying those most likely to have the disease. Some women could move from imaging to evaluation, and sometimes biopsy, in a single day.

Dr Maggie Chung, first author of the study, said: “This is a really an exciting time.

“This moves us closer to personalised care, where we can tailor a plan so that each patient gets the right intervention at the right time.”

The study used an open-source AI model called Mirai.

The model was trained on hundreds of thousands of mammograms linked to patients’ cancer outcomes.

A mammogram is an X-ray scan of the breast used to look for signs of cancer. A biopsy involves taking a small tissue sample to test for disease.

The AI tool is designed to detect subtle patterns in screening mammograms and predict a woman’s cancer risk.

Researchers at UC San Francisco and UC Berkeley applied the model to more than 4,100 screening mammograms at Zuckerberg San Francisco General Hospital and Trauma Center.

Mirai identified 525 women, about 12.7 per cent of screened patients, as high risk.

Those patients could receive an interpretation of their mammograms immediately after the scan and have additional diagnostic imaging for suspicious areas on the same day.

Some women who needed biopsies were also able to have them on the same day.

The researchers said Mirai reduced the wait time for diagnostic evaluation from several weeks to about an hour.

For women who were ultimately diagnosed with breast cancer, it reduced the average wait for biopsy from more than two months to fewer than 10 days.

The researchers stressed that Mirai does not replace radiologists or make diagnoses on its own.

Instead, it acts as a triage tool to help physicians identify the patients who can benefit most from accelerated care.

The team analysed more than 114,000 archival mammograms before launching the programme, to ensure the model would capture enough high-risk patients without overloading the clinic with too many expedited evaluations.

The researchers said they hope AI will support a more personalised approach to breast cancer screening tailored to each patient’s breast cancer risk.

Chung said: “Right now, many women follow the same screening schedule but their individual risk can be very different.

“AI risk assessment gives us the chance to identify the women most likely to benefit from expedited care and get them what they need.”

Adam Yala, senior author of the study and a data scientist at UC Berkeley, said: “This is a powerful example of how AI can be a collaborative partner for physicians.

“It shows how we can improve care when we bring clinicians and data scientists together to design these systems.”

Continue Reading

Fertility

Infertility may be risk factor for early menopause, study suggests

Published

on

Women with primary infertility may face a higher risk of early menopause and reach it about a year earlier, a study suggests.

The findings suggest women with primary infertility may be more likely to enter menopause before the age of 45.

The increased risk appeared most notable among women with unexplained infertility or a history of endometriosis.

Dr Stephanie Faubion, medical director for The Menopause Society, said: “This study shows that women with primary infertility, specifically those with unexplained infertility or a history of endometriosis, were at risk for early menopause.

“Given that early menopause is linked to adverse long-term health consequences, these women may benefit from counselling that they are at risk of early menopause.

“This will allow them to monitor for early menopause and to seek treatment with hormone therapy, if indicated.”

Early menopause is usually defined as menopause before age 45, while premature menopause is menopause before age 40.

Women who experience menopause earlier may face symptoms for longer and have a higher risk of long-term health problems.

These can include cardiovascular disease, osteoporosis and neurocognitive disorders. Osteoporosis weakens bones, while neurocognitive disorders affect memory, thinking or brain function.

The study, highlighted by The Menopause Society, involved nearly 700 people, roughly half of whom had been diagnosed with primary infertility.

It found that women with a history of primary infertility underwent natural menopause about one year earlier than those without such a history.

Researchers found no association between infertility and premature menopause.

Infertility affects around one in six people globally and can have consequences beyond family planning.

Previous research has linked infertility with higher rates of cancer and cardiovascular disease, although causes vary and may involve genetic, hormonal, in-utero or lifestyle factors.

In-utero factors are influences that occur while a baby is developing in the womb.

Earlier studies looking at links between infertility and early or premature menopause have produced mixed results, with some not accounting for different types of infertility.

The new study suggested that women with unexplained infertility or a history of endometriosis may have an increased risk of early menopause.

Endometriosis is a condition where tissue similar to the lining of the womb grows elsewhere in the body. It can cause pain, heavy periods and fertility problems.

Known risk factors for early or premature menopause include tobacco use, low body mass index, not having given birth and starting periods at a younger age.

Women who have had more childbirths and those with a history of oral contraceptive use have previously been linked to later menopause.

The researchers said women with primary infertility may benefit from additional counselling because of the systemic and long-term health effects of early menopause.

They also said women should be encouraged to seek evaluation and treatment if they experience a new loss of menstrual cycles.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.